CAMBRIDGE, Mass.—-Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data using its proprietary antagonists of Toll-like receptors 7 and 9 in mouse models of collagen-induced arthritis , a commonly used model for rheumatoid arthritis .
More: continued here